Blood thinner study aims to better protect myeloma patients from dangerous clots
NCT ID NCT06474182
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the blood thinner apixaban works in two groups of people at risk for blood clots: those with newly diagnosed multiple myeloma and those recovering from total knee replacement. Researchers want to see if the drug affects clotting differently in myeloma patients. The goal is to improve how doctors prevent clots in people with multiple myeloma.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Saint-Etienne
RECRUITINGSaint-Etienne, 42055, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact